Date: 2026-04-06 Quarter: Q4 FY2025 (Dec 2025) — FIRST PUBLIC EARNINGS (IPO Jan 28, 2026) Price: 11.89|Shares : 62.9M|MarketCap: 748M | EV: ~$430M | EV/TTM Rev: 1.1x
Look, the numbers here are really, really impressive. Revenue up 65% year over year in Q4! 98% gross margins! GAAP profitable! A Rule of 40 score of 88! And the stock is trading at just 1.1x EV/revenue??? That's just preposterous for a company growing this fast and this profitably.
But — and this is a big but — I have real concerns about carrier concentration. When 3 carriers represent something like 88-98% of your revenue, you are NOT a master of your own fate. You are dependent on a handful of powerful partners who could renegotiate your commission rates or walk away. I've seen this movie before, and it doesn't always end well.
Still, the trajectory is unmistakable, the valuation is absurdly cheap, and the business model — earning commissions with zero balance sheet risk, at 98% gross margins — is genuinely unique. This deserves a position, even if a cautious one.
Thesis: New Coverage — Cautiously Bullish. Watch carrier concentration and Q1 guidance beat.
| | Q424 | Q125 | Q225 | Q325 | Q425 | | | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---| | Revenue ($M) | 66.5 | ~89.0 | ~94.0 | ~95.0 | **110.1** | | YoY % | +66% | +58% | +34% | +53% | **+65.5%** | | QoQ % | — | +33.8% | +5.6% | +1.1% | **+15.9%** | | Gross Margin [GAAP] | 97.7% | ~98% | ~98% | ~98% | **98.1%** | | Op Margin [GAAP] | 18.8% | — | — | — | **22.2%** | | Adj EBITDA ($M) | ~15 | ~19 | ~21 | ~24 | 25.8 | | EBITDA Margin | ~22% | ~21% | ~22% | ~25% | 23% | | Policies Activated | 38,515 | 46,283 | 49,219 | 48,122 | 54,714 | | ARPU ()|1, 727|1, 920|1, 906|1, 972|**2,012** | | Contribution Margin | 39.1% | 41.6% | 40.4% | 42.1% | 42.9% |
Q1-Q3 FY25 approximate from investor presentation (company was private). Full P&L only for Q4 FY24 and Q4 FY25.
Annual Summary:
| Year | Revenue ($M) | YoY % | Adj EBITDA ($M) | EBITDA Margin | Net Income ($M) |
|---|---|---|---|---|---|
| FY2023 | 159.8 | — | ~7 | ~4% | — |
| FY2024 | 254.9 | +59.6% | 58.0 | 22.8% | 48.8 |
| FY2025 | 387.6 | +52.1% | 89.0 | 23.0% | 71.2 |
Three consecutive years of 50%+ revenue growth. From $160M to $388M in two years! And profitable the whole time! That just doesn't happen very often, folks.
65.5% YoY growth in Q4, up from +53% in Q3 and +34% in Q2. The mid-year trough in Q2-Q3 had me a little worried when I first looked at the sequential numbers (+5.6% QoQ, then +1.1% QoQ). But Q4 snapped back with +15.9% sequential growth and $15.1M in incremental revenue. That's exactly what I want to see — the growth engine is working!
The direct channel absolutely exploded: +93% YoY in Q4, up from +20% in Q3. Something changed in how Ethos is acquiring direct customers in Q4. Was it the new product launches (IUL, cancer insurance)? More agents? Better marketing conversion? I don't know — and the fact that we don't have a transcript to understand this is frustrating.
Let me say that again. 98% gross margins. Ethos earns commissions on life insurance policies. They don't hold any insurance risk — the carriers do. They don't manufacture anything. They operate a technology platform that connects consumers to life insurance through agents and carriers. The cost of revenue is basically nothing — $2M on $110M in revenue.
I've never seen gross margins this high at this scale. Not Datadog, not CrowdStrike, not anyone. And these aren't non-GAAP adjusted margins — this is GAAP!
22.2% GAAP operating margin in Q4 on $110M in revenue. Net income of $24.6M. This company is not burning cash to grow — it's generating real earnings at 65% growth rates. Rule of 40 at 88. That's elite territory.
The contribution margin (their unit economics metric — revenue minus sales & marketing minus cost of revenue) expanded to 42.9%, up from 39.1% a year ago. Each policy is generating more profit. That's operating leverage in action.
Operating cash flow went from negative $10.9M in FY2024 to positive $36.2M in FY2025. A $47M swing! Now, the cash conversion is still lagging (OCF/Net Income = 0.51x) because of the commissions receivable build-up — essentially, Ethos earns trail commissions over time that sit on the balance sheet. That's actually a GOOD thing — it means there's a growing "book" of recurring commission income from existing policies.
Third-party revenue (carrier partnerships) went from $38M in Q2 and Q3 to $35.9M in Q4 — a 5.5% sequential decline. While the direct channel was up 93% YoY, the third-party channel was only up 27%.
Why does this matter? Because the third-party channel is where carriers push volume through Ethos. If carriers are pulling back — or if growth has hit a ceiling — that challenges the "platform" narrative. Ethos claims to be the #1 source of premiums for 3 of 6 carriers. If that's true, why is third-party revenue declining sequentially?
I don't have the answer because there's no transcript. This is one of those things where I'd normally say "the CEO explained it on the call..." but we can't do that here. Frustrating!
This is my biggest concern. Ethos has 6 carriers. Based on the S-1 and analyst reports, the top 3 carriers likely represent 88-98% of revenue. That is dangerous concentration. I've always said I want companies that are masters of their own fate — companies that don't depend on a handful of large customers or partners who hold all the leverage.
Now, there's a counter-argument: Ethos is the #1 source of premiums for 3 of those 6 carriers. The carriers NEED Ethos too. That mutual dependency provides some protection. And LIMRA data shows Ethos carriers grow 2x+ faster than non-Ethos carriers. So there's real value being created.
But if a single carrier decides to bring distribution in-house, or if commission rates get squeezed, revenue could take a 30-40% hit overnight. That's the kind of risk that makes me want a smaller position size than I'd otherwise take.
I don't usually focus on valuation — I follow the money, the results. But I have to say something here because the numbers are just preposterous:
No public company I follow trades at these multiples with this growth and profitability profile. None. The median SaaS company growing 50%+ trades at 15-20x revenue. LIFE is at 1.1x.
The reason is obvious: post-IPO technical dislocation. IPO priced at $19, now at $11.89 (-37%). SoftBank invested at a $2.7B valuation in 2021 — the current market cap is $748M. They're 72% underwater. The lockup expires around late July 2026. Everyone is terrified of the selling pressure.
But here's the thing — I don't invest based on who might sell stock. I invest based on business results. And the business results are spectacular.
Q1 2026: 144−146M revenue (midpoint $145M, +53% YoY). Adj EBITDA 30−32M (~21% margin).
FY2026: 510−514M revenue (midpoint $512M, +32% YoY). Adj EBITDA 99−103M (~20% margin).
The Q1 guide of $145M is very strong — that's +32% sequentially from Q4's $110M. If they hit that, it's a $580M annualized run rate (+50% vs FY25).
The FY26 guide of $512M (+32% YoY) seems conservative to me. If Q1 is $145M, then Q2-Q4 need to average only $122M each to hit the guide. That's BELOW Q1. First-year public guidance is almost always sandbagged — management wants to build credibility by beating their numbers. I'd expect them to beat and raise.
But we have no prior guidance history to confirm this. This is literally their first public guidance ever. So I'm going on instinct here, not pattern recognition.
The EBITDA margin guiding down from 23% to ~20% for FY26 makes sense — they'll invest more in S&M as they scale the agent platform and potentially add carriers. Some margin compression in exchange for faster growth is fine.
TRANSCRIPT NOT AVAILABLE. This is the company's first public earnings call (Feb 25, 2026), and the transcript is not indexed on Motley Fool, Quartr, or other standard sources yet.
All I have is the CEO quote from the press release and the investor presentation. The CEO's tone is confident: "exceptional topline growth," "significant earnings potential," "deep commitment." But I always want to hear the Q&A. What are analysts worried about? How does management handle tough questions? Are there any "non-answer answers"? I can't assess any of that.
This is a material gap. By Q1 earnings (May 6, 2026), we should have a proper transcript to analyze.
Ethos is not SaaS. It's an insurance distribution platform that earns commission revenue. But let me explain why the economics are actually better than most SaaS companies I've owned:
The TAM is $12.6B (existing products) with only 3% penetrated. Including annuities, it's $140B+. This is still very early.
Atlas rated this 4/5 conviction. I agree with virtually all of Atlas's factual assessment — the valuation dislocation is real, the growth is exceptional, the business model is unique. Where I differ:
I weight carrier concentration more heavily. Atlas flags it but still rates "Dominance" as Strong. I think 3 carriers = 88-98% of revenue is a structural vulnerability that limits position size regardless of how good the numbers are. Masters of their own fate, people!
I'm less bothered by the lockup. Atlas lists it as Risk #2. I've seen plenty of lockup expiries that turned into buying opportunities. The business fundamentals matter more than who's selling stock in three months.
I'm more focused on the Q1 guidance beat. Atlas notes Q1 as a catalyst but doesn't emphasize enough that this is THE test. First guidance, first beat opportunity. If they miss, credibility is shot before it starts. If they beat, the re-rating begins.
This is not yet in my portfolio, and I'm treating it as a new company analysis. The numbers are exceptional — truly exceptional. Growth, margins, profitability, valuation — they all check every box. But the carrier concentration concern is real, the public track record is just one quarter, and the lockup overhang creates near-term risk.
If I were starting a position, I'd start small (2-3%) and add after Q1 earnings if: (a) they beat guidance, (b) the transcript reveals competent management, and (c) carrier concentration isn't worse than feared.
At this valuation — 1.1x EV/revenue for a 52% grower with 22% net margins — the risk/reward is heavily skewed to the upside. Even if the stock gets hit by lockup selling in July, the business fundamentals should carry it through.
Thesis Status: New Coverage — Cautiously Bullish Action: Small initial position (2-3%), with plans to add after Q1 earnings
Best, Saul
Note: Transcript unavailable for this earnings call. Analysis based on EDGAR 8-K press release and Q4 2025 Investor Presentation. Q1-Q3 FY25 data approximate from pre-IPO presentation charts.